Harrow Balance Sheet Health
Financial Health criteria checks 2/6
Harrow has a total shareholder equity of $49.3M and total debt of $222.1M, which brings its debt-to-equity ratio to 450.5%. Its total assets and total liabilities are $345.0M and $295.7M respectively. Harrow's EBIT is $14.7M making its interest coverage ratio 0.6. It has cash and short-term investments of $55.8M.
Key information
450.52%
Debt to equity ratio
US$222.10m
Debt
| Interest coverage ratio | 0.6x |
| Cash | US$55.81m |
| Equity | US$49.30m |
| Total liabilities | US$295.73m |
| Total assets | US$345.03m |
Recent financial health updates
These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively
Aug 11
Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
May 12Recent updates
Harrow's Ambitious Guidance Puts It In The Proving Ground
Aug 15
VEVYE And TRIESENCE Programs Will Expand Prescription Access
Harrow is focusing on boosting sales and profitability through patient affordability programs, strategic supply chain improvements, and next-gen product developments.Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Mar 29Harrow: A Name I Am Accumulating
Mar 19Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025
Mar 01Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price
Feb 17Harrow: The Triesence Relaunch
Dec 14Harrow: Spotlight On IHEEZO
Nov 16Harrow's Focus - Reviving Old Drugs In A Crowded Market
Oct 02Harrow: 3 Business Models, One Mission
Sep 10Borrowing Cash To Burn It: The Curious Case Of Harrow
Aug 21Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
May 02Harrow's Drug Iheezo Is Off To A Great Start
Feb 19Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Jan 30Harrow sells non‑ophthalmic compounding business, terms undisclosed
Oct 05Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye
Sep 27SRK Capital - Harrow Health: Market Missing The Forest For The Trees
Aug 19These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively
Aug 11Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch
May 23Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
May 12Financial Position Analysis
Short Term Liabilities: HROW's short term assets ($154.9M) do not cover its short term liabilities ($248.9M).
Long Term Liabilities: HROW's short term assets ($154.9M) exceed its long term liabilities ($46.9M).
Debt to Equity History and Analysis
Debt Level: HROW's net debt to equity ratio (337.3%) is considered high.
Reducing Debt: HROW's debt to equity ratio has increased from 114% to 450.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HROW has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if HROW has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/19 22:47 |
| End of Day Share Price | 2025/08/19 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harrow, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |